Assessment of the BRAF status in patients with skin melanoma

Abstract

Skin melanoma is an aggressive malignant neoplasm. Mutation of the BRAF gene, BRAF V600E, is observed in more than
70% of melanoma cases. Assessment of the BRAF status in patients suffering from skin melanoma is an important stage
in patient screening for selection of further therapy.
To reveal the mutation of BRAF V600E, 27 histology samples taken from patients with skin melanoma residing in the
Krasnodar territory were examined by means of defining the Restriction Fragment Length Polymorphism (PFLP assay).
Our studies revealed the BRAF V600E mutation in 26 of 27 histology samples of skin melanoma. It was shown that the
mutation is not associated with any sex-related, age-related, clinical and pathological features of the tumor.

References

  1. Losina E., Walensky R.P., Geller A. et al. Visual Screening for Malignant Melanoma.A Cost-effectiveness Analysis. Arch Dermatol 2007; 143: 21-28.
  2. Merabishvili V.M. Malignant Melanoma-up-todate tendencies (the morbidity, the mortality, the diagnostics). Oncological issues 2006; 3: 275-87.
  3. Пак Д.Д., Белова Е.А., Лазутина Т.Н. Исследование сторожевых лимфатических узлов у больных с меланомой кожи. Росс. онкол. журн. 2008; 4: 22-28.
  4. Garbe C., Eigentler T.K. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Research 2007; 17: 117-27.
  5. Atkins M.B., Elder D.E., Essner R., et al. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clinical Cancer Research 2006; 12: 2291-6s.
  6. Hingorani S.R., Jacobetz M.A., Robertson G.P. et al. Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Research 2003; 63: 5198-202.
  7. Satyamoorthy K., Li G., Gerrero M.R., et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Research 2003; 63: 756-9.
  8. Veenman L., Papadopoulos V., Gavish M. Channel-Like Functions of 18-kDa Translocator Protein (TSPO): Reguation of Apoptosis and steroidogenesis as Part of the Host-Defense Response. Current Pharmacology Design 2007; 13; 2385-2405.
  9. Nagasaka T., Sasamoro H., Notohara K., et al. Colorectal Cancer with Mutation in BRAF, KRAS, and Wild-Type with respect to Both Oncogenes Showing Different Patterns of DNA Methylation. J Clin Oncol 2004; 22: 4584.
  10. Solit D.B., Garraway L.A., Pratilas C.A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 358-62.

Copyright (c) 2011 Gyrylova S.N., Ruksha T.G., Zobova S.N., Komina A.V., Aksenenko M.B., GYRYLOVA S.N., RUKSHA T.G., ZOBOVA S.N., KOMINA A.V., AKSENENKO M.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies